Kodiak Sciences Inc Dossier - Source-backed chat

Kodiak Sciences Inc

KODNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.79

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $98.46Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $6.2B

Enterprise Value $6.1B

Shares Outstanding 62.7M diluted

Next Earnings Date25 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Kodiak Sciences is transitioning from a high-risk, single-asset clinical story into a diversified, late-stage vision sciences platform. Following the positive Phase 3 GLOW2 results for Zenkuda in diabetic retinopathy, the company has established a clear regulatory path with a BLA-ready asset. With a solid cash position of $169.5 million supporting operations into 2027, the upcoming DAYBREAK (September 2026) and PEAK (Q4 2026) readouts serve as major near-term catalysts that could significantly re-rate the stock.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$56.00

Mean target$69.00

High · most bullish analyst$85.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$56.0020%

DAYBREAK fails to show non-inferiority or exhibits safety concerns (e.g., intraocular inflammation), or KSI-101 fails to meet its primary endpoint in PEAK. The company is forced to delay its BLA timeline, leading to severe capital constraints and highly dilutive financing.

Base CaseCentral scenario

$69.0055%

Matches the consensus mean

DAYBREAK demonstrates non-inferior efficacy and superior durability for Zenkuda, confirming its BLA-ready status. KSI-101 shows positive Phase 3 data in MESI. Kodiak successfully files its first BLA by early 2027, with the cash runway extending comfortably into mid-2027.

Bull CaseUpside scenario

$85.0025%

Zenkuda's DAYBREAK trial meets its primary endpoints with superior durability, and KSI-101's PEAK trial delivers strong efficacy in MESI. This triggers an accelerated multi-indication BLA filing in late 2026/early 2027, positioning Kodiak to capture a significant share of the $15 billion retinal biologics market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Zenkuda is clinically validated across multiple Phase 3 trials (GLOW1, GLOW2) showing robust efficacy on extended 6-month dosing intervals.
Diversified late-stage pipeline with three distinct clinical assets (Zenkuda, KSI-501, KSI-101) targeting high-unmet-need retinal diseases.
Strong institutional backing, including significant ownership stakes from Baker Bros. Advisors and Boxer Capital.

Key Investment Risks

Pre-commercial stage with zero current revenues and substantial ongoing quarterly net losses (~$58.2 million in Q1 2026).
Binary clinical trial risks associated with the upcoming DAYBREAK (September 2026) and PEAK (Q4 2026) readouts.
Long-term funding risk, as current cash reserves of $169.5 million only fund operations into 2027, necessitating future capital raises.

Thesis Invalidation Triggers

Failure of Zenkuda to meet non-inferiority endpoints in the Phase 3 DAYBREAK wet AMD trial.
Safety signals, specifically high rates of intraocular inflammation, emerging in any of the late-stage readouts.
Inability to file the planned multi-indication BLA within the projected 2026-2027 window.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.